{"id":"NCT02132117","sponsor":"Allergan","briefTitle":"Safety and Efficacy of Oxymetazoline HCl Cream 1.0% in Patients With Persistent Erythema Associated With Rosacea","officialTitle":null,"status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-06","primaryCompletion":"2015-04","completion":"2015-05","firstPosted":"2014-05-07","resultsPosted":"2016-08-02","lastUpdate":"2019-11-18"},"enrollment":445,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Erythema","Rosacea"],"interventions":[{"type":"DRUG","name":"Oxymetazoline HCL Cream 1.0%","otherNames":[]},{"type":"DRUG","name":"Vehicle to Oxymetazoline HCL Cream","otherNames":[]}],"arms":[{"label":"Oxymetazoline HCL Cream 1.0%","type":"EXPERIMENTAL"},{"label":"Vehicle","type":"PLACEBO_COMPARATOR"}],"summary":"This study will evaluate the safety and efficacy of oxymetazoline hydrochloride (HCl) cream 1.0% (AGN-199201) once daily compared to vehicle for the treatment of persistent moderate to severe facial erythema associated with rosacea.","primaryOutcome":{"measure":"Percentage of Participants With at Least a 2-Grade Improvement (Decrease) From Baseline on Both Clinician Erythema Assessment (CEA) and Subject Self-Assessment for Rosacea Facial Redness (SSA) 5-point Scales","timeFrame":"Baseline, Day 29 (Hours 3, 6, 9 and 12)","effectByArm":[{"arm":"Oxymetazoline HCL Cream 1.0%","deltaMin":14.3,"sd":null},{"arm":"Vehicle","deltaMin":7.4,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":3},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":223},"commonTop":[]}}